Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF. Silo Pharma.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

MMJ Recs

DECEMBER 20, 2023

The establishment of medical marijuana dispensaries in Virginia represents a progressive approach to healthcare, offering patients alternative treatment options for various medical conditions. Patients diagnosed with specific medical conditions are eligible to participate in the state’s medical cannabis program.

Dispensary 52

Dispensary Marijuana Strains Patients 52

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

JULY 28, 2021

InnarisBio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders. InnarisBio aims to be a revolutionary technology company for intranasal drug delivery in the treatment of CNS disorders. A potential solution is direct nose-to-brain delivery. About atai Life Sciences.

Research and Development 98

Research and Development Programs Treatment Media 98

Cannabis Law Report

JULY 21, 2021

The treatment is designed to target nociplastic pain originating in the central nervous system through the neuroplasticity benefits of psilocybin. “Existing treatment options for fibromyalgia are often ineffective and show significant side effects,” said Daniel Clauw, M.D.,

Clinical Trials 105

Clinical Trials Chronic Pain Research and Development Treatment 105

Cannabis Law Report

JULY 12, 2019

Rachel Levine today announced that effective July 20, anxiety disorders and Tourette syndrome will be approved serious medical conditions in the medical marijuana program based on the recommendation of the Medical Marijuana Advisory Board and a review of medical research on the use of marijuana to treat these conditions.

Conditions 40

Conditions Programs Research and Development Marijuana 40

Puff Puff Post

DECEMBER 17, 2019

As a key player in a region notorious for its harsh drug laws and staunch prohibition, the country that originally seemed like an unlikely candidate to break the status quo has charged ahead with a number of breakthroughs in its new medical marijuana program. Home And Commercial Cultivation. Government Investment.

Programs 52

Programs Cultivation Recreational Strains 52

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. Diminishing efficacy of these receptors over time should be considered for proper treatment.

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

OCTOBER 14, 2021

The current state of mental health globally, existing treatments and the need for innovation. International Keynotes: Professor David Nutt (UK) – The neuroscience of new treatments. Dr Ben Sessa (UK) – MDMA-Assisted Psychotherapy for the Treatment of Alcohol Use Disorder: The results of the BIMA trial. 4:30pm – 9:00pm.

Therapy 105

Therapy Medicine Treatment Programs 105

United Patients Group

APRIL 11, 2023

Another study of patients with schizophrenia showed that probiotics taken regularly could help manage their symptoms better than placebos did Bipolar disorder Bipolar disorder is a brain disorder characterized by episodes of mania and depression. Factors There are many factors that contribute to health and wellness.

Sleep 84

Sleep Digestion Patients Food 84

Peninsula Alternative Health

JUNE 3, 2022

At Peninsula Alternative Health, we put our patients first. Way before the brick and mortar retail dispensaries, the online ordering, and the incredible patient interactions, we knew that putting the patient experience as our focus was necessary to create a strong foundation for our dispensaries and community as a whole.

Education 52

Education Patients Dispensary Vaping 52

Peninsula Alternative Health

JUNE 3, 2022

At Peninsula Alternative Health, we put our patients first. Way before the brick and mortar retail dispensaries, the online ordering, and the incredible patient interactions, we knew that putting the patient experience as our focus was necessary to create a strong foundation for our dispensaries and community as a whole.

Education 52

Education Patients Dispensary Vaping 52

Puff Puff Post

DECEMBER 17, 2019

As a key player in a region notorious for its harsh drug laws and staunch prohibition, the country that originally seemed like an unlikely candidate to break the status quo has charged ahead with a number of breakthroughs in its new medical marijuana program. Home And Commercial Cultivation. Government Investment.

Programs 40

Programs Cultivation Recreational Strains 40

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Forward-looking statements.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 2, 2021

capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. Any such forward-looking statements represent management’s estimates as of the date of this press release.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

NORML

JANUARY 9, 2019

Joyce becomes the first leader in the Caucus to come from a state that has yet to pass an adult-use regulatory program. The federal government’s interference in this arena has stifled important medical research, interfered with doctors and patients making treatment decisions and harmed state-legal businesses.

Legislation 184

Legislation Policy Cannabis Programs 184

Greencamp

OCTOBER 3, 2018

People develop PTSD after experiencing a traumatic event or an event that is perceived as such. Does cannabis aid in forgetting traumatic events or just boosts dopamine, increasing the overall feelings of pleasure? Patients can also become hypersensitive to everyday situations and feel constantly on alert. What is PTSD?

Research and Development 111

Research and Development Terpenes Events Strains 111

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

OCTOBER 4, 2021

Total medical cannabis patients in Q3 increased to more than 9,600, up 32% from Q2 2021. 62% of the patients in Q3 were returning patients, up 35% from Q2 2021. ensuring uninterrupted supply for all Khiron patients. Year to date patient visits at Khiron clinics have exceeded 104,000, topping all patient visits in 2020.

Patients 52

Patients Events Treatment Agriculture 52

Cannabis Law Report

DECEMBER 3, 2021

An analysis from continuous EEG recordings in 17 patients enrolled in the Phase 2 refractory status epilepticus (RSE) study demonstrated a substantial increase in the alpha/delta ratio immediately after the start of IV ganaxolone in 75% of patients. in patients continuing ganaxolone (n=38) and 33.3%

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

SpeedWeed

APRIL 2, 2021

The name of the event is a reference to the Realm of Caring (RoC), a nonprofit dedicated to supporting research into cannabinoids and helping patients who need them gain access to lifesaving medications. She was the sort of patient zero, if you will,” Jackson said in a virtual interview. “So She was the catalyst.

Events 52

Events Epilepsy Cannabinoids Treatment 52

CannaMD

SEPTEMBER 15, 2020

Current Florida medical marijuana patient? SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. The governor also signed Senate Bill 1700 to protect the privacy of doctors recommending low-THC marijuana and their patients.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

JULY 24, 2021

Ahmad Doroudian, Chief Executive Officer of BetterLife, stated: “TD-010 is a potential novel therapy to treat debilitating anxiety disorders that show resistance to benzodiazepine and other therapies or require a long-term use and therefore put patients at risk for dependency. Benzodiazepine Dependency. neuroscience. About Mitacs.

Research and Development 98

Research and Development Treatment Therapy Media 98

Cannabis Law Report

SEPTEMBER 24, 2021

Even the most conservative states have allowed treatment of PTSD with cannabis. Lawmakers added PTSD to the list along with cancer patients. They include anxiety, stress and processing the events that originally caused the trauma. But these events also can include a natural disaster, serious accident, terrorist act and rape.

Marijuana 52

Marijuana Events Conditions Advocacy 52

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. Highlights from the presentation include: Declining PSA levels in treated patients. Declining circulating tumor cell (CTC) count in treated patients. The full ASCO meeting program is available at: www.asco.org. Phase 2 trial underway.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

Cannabis Law Report

FEBRUARY 14, 2022

These ground-breaking treatments offer therapeutic access to either psilocybin (the active ingredient in ‘magic mushrooms’) or MDMA, a synthetic medicine. Remission rates range between 60-80% with no serious adverse events. Remission rates range between 60-80% with no serious adverse events.

Medicine 52

Medicine Access Therapy Treatment 52

Illinois News Joint

APRIL 2, 2023

To find more cannabis-friendly events in Illinois, visit here. To qualify and receive a medical patient card at a discounted rate, visit here. Below is Section 6z-112 of the State Finance Act that governs the distributions of the Cannabis Regulation Fund. For more Illinois cannabis industry news, visit here.

Education 86

Education Cannabis Collective Programs 86

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. CBD has become especially trendy in Tokyo, where CBD shops and cafes allow for the on-site consumption of CBD in edibles and topical treatments. Shutterstock). Shutterstock).

Law 137

Law Legalization Clinical Trials CBD 137

Cannabis Law Report

MAY 24, 2022

makes it abundantly clear that the cost of medical marijuana is a reimbursable expense for patients who are prescribed medical marijuana by their doctor under their worker’s compensation claim. 1] [2] The Workers’ Compensation Law also requires that treatment be rendered in accordance with its Medical Treatment Guidelines.

Chronic Pain 52

Chronic Pain Marijuana Treatment Therapy 52

Cannabis Law Report

JANUARY 19, 2022

company (TSX:LSPK) and leading virtual provider of evidence-based substance use treatment, announced today its pre-disability TRAiL Hello Premium program will now be offered to Green Shield Canada’s (GSC) plan sponsors as an optional addition to benefit plans. (Alavida), a LifeSpeak Inc. “It’s time to change that.

Programs 52

Programs Treatment Media Education 52

Cannabis Law Report

MAY 18, 2022

A recent publication in the prominent peer-reviewed journal Nature, shows that 67% of patients no longer qualified for a PTSD diagnosis a year after treatment with MDMA (or “ecstasy”). The full program can be found here. Over 40 key opinion leaders from all over the world will be participating in the event.

Research and Development 52

Research and Development Therapy Treatment Policy 52

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JUNE 3, 2021

Quinn will also serve on the Company’s Advisory Board with a focus on cannabis product development and educational programs. Quinn is a major development for the enhancement of the Company’s product roadmap and the introduction of educational cannabis programs to both the retail and consumer channels throughout California.

Research and Development 87

Research and Development Education Therapy Programs 87